NextCure and Simcere Zaiming have entered into a global strategic partnership centred on the development of SIM0505, a novel antibody–drug conjugate (ADC) that targets Cadherin-6 (CDH6). Under the agreement, NextCure retains global development and commercialisation rights outside Greater China, while Simcere Zaiming holds rights within Greater China. SIM0505 is currently undergoing a Phase 1 clinical trial.

The collaboration aims to leverage NextCure’s expertise in ADC technology and Simcere Zaiming’s regional development capabilities to advance SIM0505 toward later-stage clinical milestones. Both companies will work together to support the ongoing trial and plan for further development, with the intent to improve treatment options for patients by advancing this targeted therapeutic.